In recent years, drug companies have leveraged research into the molecular makeup of cancer cells to develop highly effective medicines for patients with specific genetic defects. The latest entry in that category: A once-a-day pill from Ignyta (RXDX). It targets defective cancer-causing genes, called ROS1, found in approximately 2 percent of lung cancer cases.

The Ignyta drug, known as entrectinib, is producing large and durable tumor responses that reach into the brain, where ROS1-positive lung cancers commonly spread, according to preliminary clinical trial results presented Tuesday at a research meeting in Japan.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy